girentuximab

(redirected from WiLex)
Also found in: Acronyms.

girentuximab

A chimeric IgG1 monoclonal antibody that targets carbonic anhydrase IX. Phase-1 and -2 studies of girentuximab plus low-dose IFN-alpha in patients with progressive metastatic renal cell carcinoma indicated that the combination therapy was safe, well tolerated and demonstrated clinical benefit in the patient population.
References in periodicals archive ?
"My job is my life and Wilex GmbH have become my family," he says.
WILEX bought in early 2009 five oncology projects from UCB.
WILEX has completed various clinical studies with the product in different indications, including two Phase II proof of concept trials for pancreatic cancer and metastatic breast cancer.
The acquisition is expected to enhance Wilex's research capabilities, while further expanding its product offerings.
This report is built using data and information sourced from Global Markets Direct's proprietary databases, Wilex AG's corporate website, SEC filings, investor presentations and featured press releases, both from Wilex AG and industry-specific third party sources, put together by Global Markets Direct's team.
- UCB TAKES FURTHER 6.65% IN GERMAN ONCOLOGY PARTNER WILEX
M2 EQUITYBITES-10 June 2010-UCB increases investment in WILEX to 18%(C)2010 M2 COMMUNICATIONS http://www.m2.com
Belgian biopharmaceutical company UCB (EBR:UCB) said on Thursday it had bought additional 6.65% in German cancer drug maker Wilex (ETR:WL6) and raised its total stake in the company to 18.05%.
M2 PHARMA-July 10, 2013-UCB obtains rights to antibody programme from Wilex for non-oncology indications(C)2013 M2 COMMUNICATIONS
Belgian biopharmaceutical company UCB (Euronext:UCB) stated on Thursday that it has increased its shareholding in WILEX AG to approximately 18%, strengthening the strategic alliance between the two firms.
Lohmann is joining MorphoSys after 11 years at Wilex AG where she was most recently senior vice president legal affairs & human resources.